Efficacy and safety of a nanofiltered liquid intravenous immunoglobulin product in patients with primary immunodeficiency and idiopathic thrombocytopenic purpura

Vox Sanguinis

Volumn 101, Issue 2, 2011, Pages 138-146

  van der Meer, J W M ^a   van Beem, R T ^b   Robak, T ^c   Deptala, A ^d   Strengers, P F W ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CENTRAL LABORATORY   (Netherlands)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

^d MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Clinical trial; Intravenous immunoglobulins; ITP; PID

Indexed keywords

CORTICOSTEROID; CREATININE; GLYCOCALICIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; NANOGAM; THROMBOPOIETIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BRONCHITIS; CHROMATOGRAPHY; CLINICAL ARTICLE; COMMON VARIABLE IMMUNODEFICIENCY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GASTROINTESTINAL INFECTION; HEADACHE; HOSPITAL ADMISSION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE DEFICIENCY; IMMUNOGLOBULIN A DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN DEFICIENCY; INFUSION RATE; KIDNEY FAILURE; KIDNEY FUNCTION; LUNG BIOPSY; MALE; MULTICENTER STUDY; NANOFILTER; OPEN STUDY; OSTEITIS; PRIMARY IMMUNODEFICIENCY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATITIS; SINUSITIS; SKIN INFECTION; THROMBOCYTE COUNT; TREATMENT DURATION; URINARY TRACT INFECTION; VIRUS INACTIVATION; X LINKED AGAMMAGLOBULINEMIA;

ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; MALE; MIDDLE AGED; NANOTECHNOLOGY; PROSPECTIVE STUDIES; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; YOUNG ADULT;

EID: 79960254962     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2011.01476.x     Document Type: Article

References (38)

1. Huston DP, Kavanaugh AF, Rohane PW, et al.: Immunoglobulin deficiency syndromes and therapy. J Allergy Clin Immunol 1991; 87(1 Pt 1):1-17.
2. Godeau B, Lesage S, Divine M, et al.: Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high-dose intravenous immunoglobulin. Blood 1993; 82:1415-1421.
3. Pacetti P, Garau D, Caramatti C, et al.: Assessment of the efficacy of a last-generation polyvalent immunoglobulin in the treatment of idiopathic thrombocytopenic purpura. Curr Med Res Opin 1997; 13:517-527.
4. Fehr J, Hofmann V, Kappeler U: Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N Engl J Med 1982; 306:1254-1258.
5. Imbach P, Barandun S, d'Apuzzo V, et al.: High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; 1:1228-1231.
6. Terpstra FG, Parkkinen J, Tolo H, et al.: Viral safety of NanogamR, a new 15nm-filtered liquid immunoglobulin product. Vox Sang 2006; 90:21-32.
7. Burnouf T, Padilla A: Current strategies to prevent transmission of prions by human plasma derivatives. Transfus Clin Biol 2006; 13:320-328.
8. Foster PR, Welch AG, McLean C, et al.: Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products. Vox Sang 2000; 78:86-95.
9. Trejo SR, Hotta JA, Lebing W, et al.: Evaluation of virus and prion reduction in a new intravenous immunoglobulin manufacturing process. Vox Sang 2003; 84:176-187.
10. Tateishi J, Kitamoto T, Mohri S, et al.: Scrapie removal using Planova virus removal filters. Biologicals 2001; 29:17-25.
11. Pruzanski W, Sussman G, Dorian W, et al.: Relationship of the dose of intravenous gammaglobulin to the prevention of infections in adults with common variable immunodeficiency. Inflammation 1996; 20:353-359.
12. Porcelijn L, Folman CC, Bossers B, et al.: The diagnostic value of thrombopoietin level measurements in thrombocytopenia. Thromb Haemost 1998; 79:1101-1105.
13. Folman CC, dem Borne AE, Rensink IH, et al.: Sensitive measurement of thrombopoietin by a monoclonal antibody based sandwich enzyme-linked immunosorbent assay. Thromb Haemost 1997; 78:1262-1267.
14. Liese JG, Wintergerst U, Tympner KD, et al.: High- vs low-dose immunoglobulin therapy in the long-term treatment of X-linked agammaglobulinemia. Am J Dis Child 1992; 146:335-339.
15. Ochs HD, Pinciaro PJ: Octagam 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases. J Clin Immunol 2004; 24:309-314.
16. Eijkhout HW, Der Meer JW, Kallenberg CG, et al.: The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial. Ann Intern Med 2001; 135:165-174.
17. Berger M, Pinciaro PJ: Safety, efficacy, and pharmacokinetics of Flebogamma 5% [immune globulin intravenous (human)] for replacement therapy in primary immunodeficiency diseases. J Clin Immunol 2004; 24:389-396.
18. Berger M: A multicenter, prospective, open label, historically controlled clinical trial to evaluate efficacy and safety in primary immunodeficiency diseases (PID) patients of Flebogamma 5% DIF, the next generation of Flebogamma. J Clin Immunol 2007; 27:628-633.
19. Orange JS, Grossman WJ, Navickis RJ, et al.: Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol 2010; 137:21-30.
20. Lucas M, Lee M, Lortan J, et al.: Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22years. J Allergy Clin Immunol 2010; 125:1354-1360.
21. Alyanakian MA, Bernatowska E, Scherrmann JM, et al.: Pharmacokinetics of total immunoglobulin G and immunoglobulin G subclasses in patients undergoing replacement therapy for primary immunodeficiency syndromes. Vox Sang 2003; 84:188-192.
22. Wolf HH, Davies SV, Borte M, et al.: Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies. Vox Sang 2003; 84:45-53.
23. Roifman CM, Levison H, Gelfand EW: High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Lancet 1987; 1:1075-1077.
24. Furst DE: Serum immunoglobulins and risk of infection: how low can you go? Semin Arthritis Rheum 2008; 39:18-29.
25. Aghamohammadi A, Moin M, Farhoudi A, et al.: Efficacy of intravenous immunoglobulin on the prevention of pneumonia in patients with agammaglobulinemia. FEMS Immunol Med Microbiol 2004; 40:113-118.
26. Julia A, Kovaleva L, Loria S, et al.: Clinical efficacy and safety of Flebogammadif, a new high-purity human intravenous immunoglobulin, in adult patients with chronic idiopathic thrombocytopenic purpura. Transfus Med 2009; 19:260-268.
27. Robak T, Salama A, Kovaleva L, et al.: Efficacy and safety of Privigen, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura. Hematology 2009; 14:227-236.
28. Bussel JB, Kimberly RP, Inman RD, et al.: Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura. Blood 1983; 62:480-486.
29. Salama A, Mueller-Eckhardt C, Kiefel V: Effect of intravenous immunoglobulin in immune thrombocytopenia. Lancet 1983; 2:193-195.
30. Bussel JB, Pham LC: Intravenous treatment with gammaglobulin in adults with immune thrombocytopenic purpura: review of the literature. Vox Sang 1987; 52:206-211.
31. Vos JJ, van Aken WG, Engelfriet CP, et al.: Intravenous gammaglobulin therapy in idiopathic thrombocytopenic purpura. Results with the Netherlands Red Cross immunoglobulin preparation. Vox Sang 1985; 49:92-100.
32. Houwerzijl EJ, Louwes H, Esselink MT, et al.: Increased glycocalicin index and normal thrombopoietin levels in patients with idiopathic thrombocytopenic purpura with a decreased rate of platelet production. Haematologica 2005; 90:710-711.
33. Kappers-Klunne MC, de Haan M, Struijk PC, et al.: Serum thrombopoietin levels in relation to disease status in patients with immune thrombocytopenic purpura. Br J Haematol 2001; 115:1004-1006.
34. von dem Borne A, Folman C, van den Oudenrijn S, et al.: The potential role of thrombopoietin in idiopathic thrombocytopenic purpura. Blood Rev 2002; 16:57-59.
35. Kocak U, Gursel T, Ozturk G: The effect of steroid and intravenous immunoglobulin on thrombopoietin levels in pediatric patients with immune thrombocytopenic purpura. Blood Coagul Fibrinolysis 2000; 11:121-125.
36. Kunishima S, Tahara T, Kato T, et al.: Serum thrombopoietin and plasma glycocalicin concentrations as useful diagnostic markers in thrombocytopenic disorders. Eur J Haematol 1996; 57:68-71.
37. Steffan A, Pradella P, Cordiano I, et al.: Glycocalicin in the diagnosis and management of immune thrombocytopenia. Eur J Haematol 1998; 61:77-83.
38. Schiff RI, Williams LW, Nelson RP, et al.: Multicenter crossover comparison of the safety and efficacy of Intraglobin-F with Gamimune-N, Sandoglobulin, and Gammagard in patients with primary immunodeficiency diseases. J Clin Immunol 1997; 17:21-28.